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ABSTRACT
Due to the rarity of relapsing polychondritis (RP), many 
unmet needs remain in the management of RP. Here, we 
present a systematic review of clinical practice guidelines 
(CPGs) published for RP, as well as a list of the most 
striking unmet needs for this rare disease. we carried out 
a systematic search in PubMed and embase based on 
controlled terms (medical subject headings and emtree) 
and keywords of the disease and publication type (CPGs). 
The systematic literature review identified 20 citations, 
among which no CPGs could be identified. we identified 
11 main areas with unmet needs in the field of RP: the 
diagnosis strategy for RP; the therapeutic management of 
RP; the management of pregnancy in RP; the management 
of the disease in specific age groups (for instance in 
paediatric-onset RP); the evaluation of adherence to 
treatment; the follow-up of patients with RP, including the 
frequency of screening for the potential complications 
and the optimal imaging tools for each involved region; 
perioperative and anaesthetic management (due to 
tracheal involvement); risk of neoplasms in RP, including 
haematological malignancies; the prevention and 
management of infections; tools for assessment of disease 
activity and damage; and patient-reported outcomes and 
quality of life indicators. Patients and physicians should 
work together within the frame of the ReCONNeT network 
to derive valuable evidence for obtaining literature-
informed CPGs.
InTroduCTIon
Relapsing polychondritis (RP) is a systemic 
inflammatory disease primarily affecting 
the cartilaginous structures of the ears, 
nose and tracheobronchial tree, but also 
the joints, the inner ear, the eyes and the 
cardiovascular system.1 The first case of RP 
was described in 1923 by Jaksch-Warten-
horst,2 but little attention has been given 
to the entity until the 1960s, when Pearson 
et al3 introduced the name ‘relapsing poly-
chondritis’. The classification criteria for 
RP by Michet et al4 require the presence 
of proven inflammation in at least two of 
three of the auricular, nasal or laryngotra-
cheal cartilages, or proven inflammation in 
one cartilage plus two other signs, including 
ocular inflammation, vestibular dysfunc-
tion, seronegative inflammatory arthritis or 
hearing loss. RP is a chronic disease with a 
flaring-remitting course. The exact cause of 
RP is still unknown, but the disease is mostly 
regarded as an immune-mediated disease,5 
as there is a well-documented overlap of 
RP with other rheumatic and autoimmune 
diseases.4 6 Moreover, RP is strongly associ-
ated with the Human Leucocyte Antigen 
(HLA) allele DR4, and various immune 
responses directed against cartilage compo-
nents have been demonstrated in patients 
with RP.5 Since RP is a very rare disease, with 
a prevalence estimated to be as low as a few 
cases per million,7 8 it remains an under-re-
searched area. Scores for assessing both 
disease activity and damage in RP have been 
developed by our group, with the help of a 
panel of international experts.9 Importantly, 
due to the rarity of the disease, the lack of 
Key messages
What is already known about this subject?
 ► Due to the rarity of the disease and the paucity of 
available evidence, many unmet needs remain in the 
field of relapsing polychondritis (RP).
What does this study add?
 ► we performed a systematic review of clinical prac-
tice guidelines published for RP, and we identified 
the most striking unmet needs in this rare disease.
How might this impact on clinical practice?
 ► Due to the extreme rarity of the disease, patients and 
physicians should work together within the frame 
of the ReCONNeT network to derive valuable evi-
dence for informing literature-based clinical practice 
guidelines for RP.
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Figure 1 Flow chart showing the study selection process.
adequate networks of care for RP in most countries and 
the paucity of drug efficacy data, many unmet needs 
remain in the field of RP. Here we present a systematic 
review of clinical practice guidelines (CPGs) published 
for RP, as well as a list of the most striking unmet needs 
in this rare disease. The review has been carried out 
under the framework of the European Reference 
Network on Rare and Complex Connective Tissue and 
Musculoskeletal Diseases (ERN ReCONNET), gath-
ering the experience of several European centres with 
experience in the diagnosis and follow-up of RP and 
involving patient representatives.
MeTHods
We carried out a systematic search in PubMed and 
Embase based on controlled terms (medical subject 
headings (MeSH) and Emtree) and keywords of the 
disease and publication type (CPGs). We reviewed all 
the published articles in order to identify existing CPGs 
on diagnosis, monitoring and treatment, according to 
the definition of the Institute of Medicine 2011 (CPGs 
are statements that include recommendations intended 
to optimise patient care that are informed by a system-
atic review of evidence and an assessment of the bene-
fits and harms of alternative care options). The disease 
coordinator (DC) of the ERN ReCONNET for RP has 
assigned the work on CPGs to the healthcare providers 
involved. Moreover, in order to implement the list 
of guidelines provided by the Medline and Embase 
search, the group also performed a hand search. A 
first screening among papers included in the final list 
(systematic search + hand search) based on title and 
abstract selected evidence-based medicine guidelines. 
A general assessment of the CPGs has been performed 
following the Appraisal of Guidelines for Research & 
Evaluation II (AGREE II) tool checklist not for formal 
appraisal but only to inform discussion. A discussion 
group was set for the evaluation of the existing CPGs 
and to identify the unmet needs.
Here is the search strategy: Medline (PubMed): (“poly-
chondritis, relapsing” [MeSH Terms] OR (“polychondritis” 
[All Fields] AND “relapsing” [All Fields]) OR “relapsing 
polychondritis” [All Fields] OR (“relapsing” [All Fields] AND 
“polychondritis” [All Fields]) AND (“Practice Guideline” 
[Publication Type] OR “Practice Guidelines As Topic” [MeSH 
Terms] OR Practice Guideline [Publication Type] OR “Prac-
tice Guideline” [Text Word] OR “Practice Guidelines” [Text 
Word] OR “Guideline” [Publication Type] OR “Guidelines 
As Topic” [MeSH Terms] OR Guideline [Publication Type] 
OR “Guideline” [Text Word] OR “Guidelines” [Text Word] 
OR “Consensus Development Conference” [Publication Type] 
OR “Consensus Development Conferences As Topic” [MeSH 
Terms] OR “Consensus” [MeSH Terms] OR “Consensus” 
[Text Word] OR “Recommendation” [Text Word] OR “Recom-
mendations” [Text Word] OR “Best Practice” [Text Word] OR 
“Best Practices” [Text Word]). Embase: (‘relapsing polychon-
dritis’/exp OR ‘atrophic polychondritis’ OR ‘chronic atrophic 
polychondritis’ OR ‘chronic atropic polychondritis’ OR ‘chronic 
polychondritis, atrophic’ OR ‘polychondritis, relapsing’ OR 
‘relapsing polychondritis’) AND (‘practice guideline’/exp OR 
‘practice guideline’ OR ‘practice guidelines’/exp OR ‘practice 
guidelines’ OR ‘clinical practice guideline’/exp OR ‘clinical 
practice guideline’ OR ‘clinical practice guidelines’/exp OR 
‘clinical practice guidelines’ OR ‘clinical practice guidelines 
as topic’/exp OR ‘clinical practice guidelines as topic’ OR 
‘guideline’/exp OR ‘guideline’ OR ‘guidelines’/exp OR ‘guide-
lines’ OR ‘guidelines as topic’/exp OR ‘guidelines as topic’ OR 
‘consensus development’/exp OR ‘consensus development’ OR 
‘consensus development conference’/exp OR ‘consensus devel-
opment conference’ OR ‘consensus development conferences’/
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Box 1 unmeet needs in the field of relapsing 
polychondritis (rP)
Major unmet needs in the field of RP.
 ► The diagnosis strategy for RP.
 ► The therapeutic management of RP.
 ► The management of pregnancy in RP.
 ► The management of the disease in specific age groups (for instance 
in paediatric-onset RP and its relationship with growth, or in the 
geriatric population).
 ► The evaluation and management of adherence to treatment.
 ► The follow-up of patients with RP, including the frequency of screen-
ing for the potential complications, mainly of respiratory, cardiac, 
aortic, ocular and joint involvement, and the optimal imaging tools 
for each involved region.
 ► Perioperative and anaesthetic management (due to tracheal 
involvement).
 ► Risk of neoplasms in RP, including haematological malignancies, 
and the need for screening for an occult neoplasm.
 ► The prevention and management of infections.
 ► Tools for assessment of disease activity and damage.
 ► Patient-reported outcomes and quality of life indicators.
exp OR ‘consensus development conferences’ OR ‘consensus 
development conferences as topic’/exp OR ‘consensus develop-
ment conferences as topic’ OR ‘consensus’/exp OR ‘consensus’ 
OR ‘recommendation’ OR ‘recommendations’) AND [embase]/
lim NOT [medline]/lim.
resulTs
state of the art on CPGs
The systematic literature review identified 20 citations, 
among which no CPGs could be identified (figure 1).
unmet needs
Clinicians’ unmet needs
Following extensive discussions between the DC and 
other members of the ReCONNET network, we identi-
fied 11 main areas with unmet needs in the field of RP 
(box 1). We also report detailed list of clinical manifesta-
tions that may be seen in RP (table 1).
The diagnostic strategy for RP
The classical classification criteria for RP (such as those 
by Michet et al,4 McAdams or Damiani-Levine) have been 
empirically postulated. The disease is rare and difficult to 
recognise early, especially in the absence of typical carti-
lage involvement. The diagnostic delay is associated with 
the lack of ear, nose or joint involvement.10–13 Early signs 
of RP in such cases may be intermittent arthritis or eye 
involvement such as episcleritis and scleritis, which may 
point a search for RP. However, even in the presence of 
external ear inflammation, an infection, local trauma, 
insect bite and chondrodermatitis nodularis helicis 
(Winkler’s disease) are often suspected first.
The diagnosis of RP is mostly clinical, and may be 
informed by laboratory data, imaging techniques and 
occasionally cartilage biopsies. RP mimickers such as 
granulomatosis with polyangiitis (GPA), T-cell lymphoma, 
sarcoidosis and so on have to be differentiated from 
RP. Moreover, another immune-mediated disease, such 
as systemic lupus erythematosus, Sjogren’s syndrome, 
vasculitis, antiphospholipid syndrome, rheumatoid 
arthritis, spondyloarthritis, inflammatory bowel disease, 
thyroiditis and others, is associated with RP in up to 30% 
of cases and should be searched for systematically. On 
diagnosis, a baseline assessment is necessary in order to 
evaluate disease activity, organ involvement and disease 
damage, and to identify potentially associated diseases. 
A typical baseline assessment may include otorhinolaryn-
gology and ophthalmology examinations, cardiovascular 
screening for valvulopathies and aortic involvement, 
pulmonary assessment, renal function testing, testing 
for antineutrophil cytoplasmic autoantibodies (ANCAs) 
and possibly haematological assessment to rule out myel-
odysplastic syndrome (MDS).14 However, the frequency 
of these assessments is not standardised and may require 
further validation.
To date, there is a real need for validated diagnostic 
biomarkers in RP, as well as markers predictive of disease 
activity, specific organ involvement or prognosis. There is 
no characteristic laboratory analysis in RP. An inflamma-
tory syndrome is present in more than 60% of patients, 
but is not constant during flares.15 Antinuclear antibodies 
with no particular specificity and ANCA, mostly atypical 
in immunofluorescence, with no proteinase 3 (PR3) or 
myeloperoxidase (MPO) specificity, have been reported 
in several series.15 The potential candidate biomarkers, 
the anticollagen type II antibodies and antimatrilin type I 
antibodies, are neither sensitive nor specific enough.1 14 16 
Moreover, cartilage biopsy is positive only in two-thirds 
of cases and does not show any specific change3 15 17; its 
added value is therefore limited.
Several potential disease activity markers such as anti-
collagen type II antibodies, antimatrilin-I antibodies, 
other autoantibodies targeting collagen structures 
(serum cartilage oligomeric matrix protein, urinary type 
II collagen neoepitope) or interferon-gamma, inter-
leukin (IL)-12 and IL-2 and serum soluble triggering 
receptor expressed on myeloid cells 1 (sTREM-1) have 
been reported to parallel the flares.5 None of these have 
entered clinical practice.
Mortality in RP is more than double compared with the 
general population; the most frequent causes of death 
are respiratory, cardiac and haematological involve-
ment.12 Three phenotypes with different presentations 
have been recently described in a cluster analysis of a 
cohort: a haematological form (in 10% of cases), a respi-
ratory form (in 25%) and a mild one with good prog-
nosis (about 65% of cases).15 Some complications such as 
aortitis,18 vasculitis4 or anaemia are pejorative prognosis 
factors.4 In addition, the male gender is associated with 
worse prognosis and higher prevalence of uveitis, hearing 
loss, vestibular disorder, as well as greater necessity for 
methylprednisolone and cyclophosphamide pulses.19
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Table 1 Main clinical features of RP and proposed management (expert opinion)
Main clinical manifestations Typical therapeutic management* (based on expert opinion)
Nasal or auricular chondritis.
Peristernal chondritis.
NSAIDs, GCs. In case of relapsing disease colchicine, dapsone, methotrexate or other 
conventional immunosuppressive agents or biologics.
Tracheal chondritis. GCs, methylprednisolone infusion, csDMARDs, conventional immunosuppressive 
agents (eg, cyclophosphamide) or biologics.
Articular manifestations.
Peripheral and/or axial involvement.
NSAIDs, GCs, csDMARDs, conventional immunosuppressive agents (eg, methotrexate) 
or biologics.
Cutaneous involvement.
 ► Aphtosis.
 ► Nodules.
 ► Cutaneous vasculitis.
GCs, colchicine, dapsone (especially in case of neutrophilic dermatitis), methotrexate.
Cardiac involvement.
Valvular involvement.
 ► Pericarditis.
 ► Myocarditis.
 ► Aortitis.
GCs, csDMARDs, conventional immunosuppressive agents (eg, methotrexate) or 
biologics.
Ocular involvement.
 ► Episcleritis.
 ► Scleritis.
Topical GCs, cycloplegic. All patients with ocular involvement should be referred to an 
ophthalmologist. csDMARDs, conventional immunosuppressive agents or biologics 
may be necessary.
Audiovestibular dysfunction.
 ► Sensorineural deafness.
 ► Vestibular dysfunction.
GCs, methylprednisolone infusion, csDMARDs, conventional immunosuppressive 
agents or biologics.
Neurological manifestations.
 ► Sensorimotor neuropathy.
 ► Encephalitis.
GCs, methylprednisolone infusion, csDMARDs, conventional immunosuppressive 
agents (eg, cyclophosphamide) or biologics.
Renal involvement. In most cases, renal involvement suggests differential diagnoses such as ANCA-
associated vasculitis.
*The proposed therapeutic strategy should take into account disease severity and patient individual characteristics/contact one of the 
ReCONNET centre for RP when appropriate.
ANCA, antineutrophil cytoplasmic autoantibodies; GCs, glucocorticoids;NSAIDs, non-steroidal anti-inflammatory drugs;RP, relapsing 
polychondritis; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs.
The therapeutic management of RP
The treatment in RP is mostly based on case reports and 
case series. The therapy is selected according to the clin-
ical picture and its severity, and depends on the type of 
organ involvement. Minor nasal or auricular chondritis 
may respond to non-steroidal anti-inflammatory drugs, 
glucocorticoids,11 colchicine or dapsone. Conventional 
disease-modifying antirheumatic drugs (cDMARDs) are 
employed as glucorticoid-sparing agents or in cases of 
more severe disease: methotrexate, azathioprine, ciclo-
sporin, leflunomide, mycophenolate mofetil, cyclophos-
phamide and so on, sometimes in a ladder-step incre-
ment.11 No clinical trials have been published on biologics 
in RP.11 20 In a recent French series,21 the biologic agents 
used to treat RP included tumour necrosis factor inhib-
itors (among which adalimumab was shown to have the 
best remanence), tocilizumab, anakinra, rituximab and 
abatacept.
Strikingly, only 2/3 of patients responded to treatment 
at 6 months, with a complete response observed in 19% 
of cases.
The management of eye involvement is critical, 
because necrotising scleritis is commonly associated with 
significant morbidity and may lead to ocular perforation. 
Patients should be referred to an ophthalmologist as 
early start of local and systemic therapy may avoid further 
complications. While minor cases such as episcleritis may 
be managed using topical treatments, the most severe 
cases usually prompt aggressive systemic treatment such 
as glucocorticoid and cyclophosphamide infusions. Cases 
of necrotising scleritis treated with biologics (infliximab 
or adalimumab) have also been reported.10 11 The use 
of cyanoacrylate glue repairment has been reported for 
peripheral corneal perforations.22
The management of respiratory airway involvement 
depends on its presentation and severity. About 25% 
of cases will develop a laryngotracheal stricture.23 Early 
signs of tracheobronchomalacia should be searched for. 
Tracheal narrowing can be addressed by tracheostomy, 
tracheal dilation, stenting and reconstructive surgery.11 
However, it is not clear whether these procedures do not 
aggravate RP, as they may result in distal airway inflamma-
tion.14 Due to the risk of tracheal perforation, pulmonary 
fibroscopy should generally be strongly discouraged in 
RP. When absolutely needed, the procedure should be 
performed only by very skilled pneumologists, with the 
backup of an intensive care unit. Nasal reconstructive 
surgery has controversial results; bone grafts are mostly 
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preferred (skull or iliac bone) since common cartilage 
may become inflamed after trauma; however L-shaped 
costal cartilage has been employed successfully in disease 
remission under immunosuppressants.14 24
The management of arthritis is also non-codified. In 
most cases, the episodes of arthritis are self-limited and 
non-erosive and its occurrence does not parallel other 
disease features. The costochondral, sternoclavicular and 
manubriosternal joints, as well as the peripheral large 
and small joints, may be involved, sometimes in an asym-
metric manner.25 cDMARDs, sometimes in combination 
with biologic therapy, may be required.
In a recent large study, aortic involvement, consisting of 
aneurysms or ectasia, mainly of the thoracic and abdom-
inal aorta, occurred in 6.4% of cases, after a median 
follow-up of 2 years.18 An older study showed that a close 
vascular follow-up is needed in RP and that reinterven-
tion may be necessary in some cases.26 In a recent series, 
up to 22% of patients had a cardiac valvulopathy, usually 
not severe.15 Periodic echocardiography may detect the 
progression of a valvulopathy despite the apparent quies-
cence of RP.27
The existence of a renal involvement is a controversial 
issue in RP, because in most cases the correct diagnosis is 
not RP but GPA or microscopic polyangiitis.15
The skin involvement is non-specific, including neutro-
philic dermatosis, cutaneous vasculitis, nodules, aphthae, 
superficial venous thrombosis and so on. Chronic skin 
lesions are more frequent in patients with late-onset RP 
and are associated with MDS.28 29
The management of pregnancy in RP
The management of pregnancy in RP relies on scarce data. 
In a case series of 25 pregnancies in 11 women, 1 elective 
medical termination was performed due to cyclophos-
phamide therapy; flares occurred in 7 of the remaining 24 
cases, while the disease was considered stable in 16 cases 
and asymptomatic in 1.30 RP onset during pregnancy, at 
about 20 weeks of gestation, has also been published. No 
evidence of neonatal RP was observed in neonates, but 
the risk of fetal loss was increased.30
RP in specific age groups
A systematic review of paediatric-onset RP identified the 
most common presenting features to be joint pain, ocular 
inflammation and chondritis.31 Paediatric RP shares 
many features with adult RP; however, children frequently 
have a familial history of autoimmunity and usually do 
not have associated autoimmune diseases. The outcome 
may be fatal, mostly due to cardiac complications; hence, 
the screening for complications is mandatory. Growth 
does not seem to be impaired by cartilage involvement,31 
although there are exceptions with regard to the epiphysia 
plate involvement and destructive arthritis.32 Increased 
MRI bone marrow signal of unclear significance has been 
reported in two children.33 In very young children, the 
monogenic autoinflammatory disease chronic atypical 
neutrophilic dermatosis with lipodystrophy and elevated 
temperature (CANDLE) proteasome-associated autoin-
flammatory syndrome (PRAAS) (CANDLE (PRAAS)) 
due to proteasome mutations (PSMB8) may evolve with 
polychondritis features (auricular chondritis, nodular 
episcleritis and keratitis, along with widespread inflam-
mation and lipodystrophy).34
In the elderly, the presence of chondritis may point to 
an associated vasculitis or to an MDS, more frequent in 
this age group. Previous age-related cardiac and respira-
tory involvement may affect the prognosis in the pres-
ence of silent valvular or respiratory disease due to RP.15
The evaluation and management of adherence to treatment
There are no data referring to the adherence to therapy 
and its evaluation in patients with RP.19 This issue needs 
to be addressed, mostly in patients with a refractory 
disease that fails to respond to conventional therapy.
The follow-up and the optimal imaging tool
Follow-up of patients with RP includes screening for 
potential complications, mainly of respiratory, cardiac, 
aortic, ocular and joint involvement, as well as a proac-
tive assessment of complications (at least respiratory, 
cardiac, ocular and otorhinolaryngological). The optimal 
frequency of the assessment is not known. However, in a 
recent study, aortic complications were detected at ≈2 
years from diagnosis.18 Arthritis and the ocular features 
may be inaugural or may appear anytime during the 
disease. For respiratory involvement, a thorax CT scan35 
may reveal oedematous tracheobronchial wall thick-
ening with or without mural calcifications, deformity of 
cartilaginous structures, and narrowing of the trachea 
and bronchi. A typical feature is that the posterior part 
of the trachea (membranous trachea) is usually spared 
in case of early tracheal involvement, which is suggestive 
of RP. Dynamic examinations may reveal air structures 
collapse.13 CT scan of the neck may reveal thickening, 
calcification or destructive lesions of the larynx carti-
lages (such as cricoid or thyroid cartilage).36 Thoraco-
abdominal CT scan identifies the aortic involvement.18 
Also not fully validated, several reports suggest that 
18F-fluorodeoxyglucose Positron Emission Tomography 
(18F-FDG PET/CT) could be interesting for thera-
peutic response monitoring as the uptake may diminish 
or disappear after therapy.37 For articular involvement, 
Tc-99m bone scintigraphy may reveal active sites of 
inflammation.38 Cerebral MRI may be useful if central 
nervous system involvement is suspected.39 Otorhinola-
ryngoscopic examination reveals conductive and senso-
rineural hearing loss in about 40% of cases, sometimes 
along with nasal ulcerations, septal perforations, saddle 
nose deformity, arytenoid swelling and vocal cords 
deformities.13 Pulmonary spirometry, including inspira-
tory volumes, may help assess the tracheal involvement. 
Ophthalmoscopic examination may reveal any type of 
structure involvement (conjunctivitis, episcleritis, kera-
titis, uveitis, retinopathy, glaucoma, dacryocystitis and 
so on), the most dreaded being necrotising scleritis or 
 o
n
 11 February 2019 by guest. Protected by copyright.
http://rm
dopen.bmj.com/
R
M
D
 O
pen: first published as 10.1136/rm
dopen-2018-000788 on 18 O
ctober 2018. Downloaded from
 
6 Rednic S, et al. RMD Open 2018;4:e000788. doi:10.1136/rmdopen-2018-000788
RMD Open
Table 2 The Relapsing Polychondritis Disease Activity 
Index (RPDAI), adapted from Arnaud et al9
Points Points
Constitutional symptoms Cutaneous 
manifestations
2   Fever (>38°C/100.4°F) 3   Purpura
Rheumatological 
manifestations
Renal 
manifestations
1   Arthritis 4   Haematuria
Chondritides 6   Proteinuria
3   Manubriosternal 
chondritis
17   Renal failure
4   Sternoclavicular 
chondritis
Cardiovascular 
manifestations
4   Costochondritis 9   Pericarditis
9   Auricular chondritis (can 
be unilateral or bilateral)
16   Large-sized and/
or medium-
sized vessel 
involvement
9   Nasal chondritis 17   Myocarditis
Ophthalmological 
manifestations
18   Acute aortic or 
mitral insufficiency
5   Episcleritis Neurological 
manifestations
9   Scleritis 12   Motor or 
sensorimotor 
neuropathy
9   Uveitis 22   Encephalitis
11   Corneal ulcer
Respiratory 
manifestations
14   Retinal vasculitis Respiratory 
chondritis (laryngeal 
and/or tracheal 
and/or bronchial 
chondritis)
Biological data 14   Without acute 
respiratory failure
3   Raised C reactive 
protein (>20 mg/L)
24   With acute 
respiratory failure
ENT manifestations   Other (please 
explain):
8   Sensorineural deafness   
12   Vestibular dysfunction   
  TOTAL RPDAI 
SCORE
The scoring should only take into account manifestations attributable 
to relapsing polychondritis and present during the last 28 days.
ENT, ear, nose and throat.
peripheral ulcerative keratitis, which may rapidly lead to 
eye loss.1
Perioperative and anaesthetic management
In case of surgery, the anaesthesiologist should be 
informed of the risk of airway damage during intuba-
tion,40 tracheal stenosis or tracheobronchomalacia, stric-
tures and scars in the cricoarytenoid area, or dynamic 
airway obstruction.40 Anaesthesia may be converted to 
epidural analgesia whenever possible. A careful preoper-
ative assessment should be planned and the anaesthesiol-
ogist may need to prepare various sizes of tracheal tubes 
and other airway manipulation devices.41
The risk of neoplasms
Haematological malignancies, mainly MDS, but also 
lymphoma including mucosa-associated lymphoid tissue, 
myeloproliferative neoplasms, multiple myeloma and 
others, and more rarely solid cancers (lung, breast, colon, 
urothelial carcinoma, sarcoma), have been described in 
11%–13% of cases, mainly in male patients with late-
onset RP (>60 years) and in those with cutaneous involve-
ment, mostly neutrophilic dermatosis.15 28 42 The reasons 
for this association are still occult. There are no guide-
lines regarding the type and frequency of screening for 
occult neoplasia in RP.43 Exophthalmos in patients with 
RP should prompt the search for lymphoma or IgG4-as-
sociated disease.44
The prevention and management of infections
Infections are responsible for the significant morbidity (up 
to 35%) in the respiratory phenotype patients.15 Secretion 
clearance is impaired in patients with airway involvement. 
In addition, the risk of infections is higher in patients with 
an underlying MDS or diabetes. Steroids and biologic 
therapy administration may be complicated by systemic 
infections in such patients (45). There are no guidelines 
regarding infection prophylaxis and therapy in patients 
with RP, but it is reasonable to believe that the general 
recommendations used in immunocompromised patients 
should apply in patients with RP with immunosuppressive 
treatments.
Tools for assessment of disease activity and damage
As RP is a remitting-relapsing disease, disease activity has 
to be recorded during follow-up. The Relapsing Polychon-
dritis Disease Activity Index (RPDAI) has been designed to 
assess RP in a standardised manner, taking into account the 
disease manifestations over a 28-day period. The RPDAI 
consists of 27 items with individual weights, ranging from 
1 to 24, and reaches a maximum theoretical score of 265.9 
More important, as there are no biologic disease activity 
markers in use, the RPDAI is a useful instrument to assess 
disease activity in multiple systems, as well as to assess thera-
peutic response, even in patients with no current inflamma-
tory syndrome (table 2). A damage index has been recently 
developed (Arnaud 2018, in press) to assess the disease-in-
duced irreversible changes, with the aim to standardise the 
assessment and to facilitate studies in this rare disease.
Patient-reported outcomes and quality of life indicators
A recent study on more than 300 patients revealed that 
over 50% have visited the emergency room, had symptoms 
for more than 5 years and have consulted more than three 
physicians prior to diagnosis.13 The diagnostic delay (>1 
year) was attributed to coexisting fibromyalgia and to the 
lack of auricular and nasal chondritis and arthritis.13 Some 
patients may need long-term glucocorticoids and therefore 
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develop complications associated with the therapy (arte-
rial hypertension, diabetes mellitus and so on).19 Disease 
burden is high and includes disability (25%), hearing loss 
(34%) more prevalent in patients with joint involvement, 
and tracheomalacia (16%) in patients with respiratory 
involvement. From this perspective, relevant unmet needs 
are timely diagnosis, standards for therapy, and prevention 
of disease-related and therapy-related complications.13 No 
self-reporting instruments for patients with RP are available; 
there are no data regarding the quality of life indicators in 
patients with RP. Both the RPDAI and the Relapsing Poly-
chondritis DAmage Index (RPDAM) have been derived 
using the Delphi method and/or patient case exercises, 
as well as using additional feedback from international 
experts. Those have not been validated prospectively and 
their detailed psychometric properties, including sensitivity 
to change and minimal clinically important difference, 
remain currently unknown.
Patients’ unmet needs
Most patients are in need of a continuity of care and 
follow-up, in particular through a multidisciplinary team 
approach. When there is extensive RP damage, many 
different appointments are needed for different special-
ists who do not always communicate with each other or 
are aware of the disease. There is also a need for a better 
diagnostic approach, as well as a team that helps patients 
after the diagnosis with reasonable adjusted advice about 
employment and disability. It is mainly the care and ther-
apeutic approach that is of most importance for patients. 
There is a lack of knowledge, not enough studies available, 
as well as no specialised clinical and research teams avail-
able for most patients. RP damage can have a big impact 
on the well-being of patients. The patients, caregivers and 
medical caregivers therefore need to be further educated 
to help in the assistance of patients with RP. The ERN 
ReCONNET could help play a major role in this matter.
ConClusIon
This systematic review shows that there are currently no 
CPGs available for RP. Given the limited data on the patho-
genesis of the disease, the association of clinical and labo-
ratory manifestations or imaging strategies, we were able 
to identify several major unmet needs. To the extreme 
rarity of the disease, patients and physicians should work 
together within the frame of the ReCONNET network to 
derive valuable evidence for the derivation of literature-in-
formed CPGs.
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